The company has Rs 64 bn in cash and equivalents on its balance sheet, plus another Rs 45 bn in…
The company has Rs 64 bn in cash and equivalents on its balance sheet, plus another Rs 45 bn in…
MSS’ net debt as of Mar’20 stood at an 11-quarter low of Rs 71.5 bn at a consolidated level and…
However, social distancing and the eventual lockdown in many geographies (where GCPL operates), resulted in virtually no sales in the…
FY21/22e EPS up 6.4/3.8%; TP raised to Rs 535; ‘Neutral’ retained as return ratios are yet to improve significantly
Stability in operations may be delayed until Q3FY21; earnings estimates changed and TP cut to Rs 1,300 from Rs 1,617;…
The Naukri JobSpeak Index for Mar’20 marked decline of 18% in hiring activity against that in Mar’19.
In view of the nationwide lockdown, all offices have been shut down an production at units that manufacture essential food…
FY21/22e Ebitda down 25/4% given slump in power demand; CIL’s cash position a positive; ‘Buy’ retained with TP of Rs…
BEL has demonstrated strong execution capability over the years and is well placed in the current troublesome time of Covid-19.
The near-term outlook is challenging amid economic stress across sectors due to the lockdown, which has added pain to the…
TMX has significant operations in Pune, and even prior to the nationwide lockdown, it had started implementing work-from-home and other…
We cut our FY20-22 earnings estimate by 8-22% and Sep’21E EPS based TP to Rs 855. Note that we forecast…
Sales were marginally lower as BS4 inventory is almost exhausted and customers are postponing purchases.
Voltas is adequately covered with respect to supplies in RACs till April end. Inventory in channel stands at 55-60 days,…
Sales of some retail goods up due to Covid-19; govt curbs could hit business but prospects bright over next 2…
There was need to simplify shareholding structure of HLFL for it to pursue future growth opportunities like getting another PE…
The group is facing no credit squeeze from any financiers and has enough liquidity available in all operating entities.
Recently, the USFDA issued a warning letter to this site, citing inadequate response to observations highlighted in form 483.